Payment overview · 2025
General Payments
$35,236.34
83 reported records · 3 companies
Healthcare provider profile · identity verified
Abraham Alejandro Vandiver, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ESCONDIDO, CA · NPI 1982176947
Verified facts
What the public records show
CMS Open Payments records show Abraham Alejandro Vandiver, FNP received $35,236.34 in general payments during 2025 across 83 reported records.
Corcept Therapeutics accounted for 99.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Korlym, Ozempic, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ubrelvy by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Korlym by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 507 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34,874.47 | 99.0% | 72 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $225.97 | 0.6% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.90 | 0.4% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,141.00 | 16 |
| Travel and Lodging | $5,327.62 | 18 |
| Honoraria | $3,198.00 | 2 |
| Food and Beverage | $2,019.72 | 45 |
| Consulting Fee | $550.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34,874.47 | 72 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $201.24 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $135.90 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $76.75 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $10.90 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Korlym korlym |
2025 | Korlym | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 507 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 291 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
78 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
507 | 83 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
291 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metformin Hcl Er | Metformin Hcl | 1004 | 161 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 883 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 796 | 137 |
| Losartan Potassium | Losartan Potassium | 688 | 103 |
| Ozempic | Semaglutide | 507 | 83 |
| Farxiga | Dapagliflozin Propanediol | 487 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 393 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 76 |
| Dapagliflozin | Dapagliflozin Propanediol | 334 | 75 |
| Lisinopril | Lisinopril | 312 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 297 | 60 |
| Rybelsus | Semaglutide | 291 | 42 |
| Icosapent Ethyl | Icosapent Ethyl | 283 | 50 |
| Alendronate Sodium | Alendronate Sodium | 193 | 41 |
| Repatha Sureclick | Evolocumab | 182 | 25 |
| Kerendia | Finerenone | 179 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 25 |
| Vascepa | Icosapent Ethyl | 165 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 27 |
| Carvedilol | Carvedilol | 142 | 21 |
| Gabapentin | Gabapentin | 126 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 123 | 31 |
| Telmisartan | Telmisartan | 111 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 22 |
| Bupropion Xl | Bupropion Hcl | 101 | 14 |
| Meloxicam | Meloxicam | 79 | 22 |
| Korlym | Mifepristone | 78 | 11 |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 77 | 13 |
| Praluent Pen | Alirocumab | 70 | suppressed |
| Simvastatin | Simvastatin | 65 | suppressed |
| Omeprazole | Omeprazole | 63 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 11 |
| Trazodone Hcl | Trazodone Hcl | 61 | 18 |
| Montelukast Sodium | Montelukast Sodium | 60 | 14 |
| Allopurinol | Allopurinol | 56 | suppressed |
| Finasteride | Finasteride | 55 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | suppressed |
| Valsartan | Valsartan | 49 | suppressed |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Ibuprofen | Ibuprofen | 47 | 37 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Eplerenone | Eplerenone | 45 | suppressed |
| Spironolactone | Spironolactone | 45 | suppressed |
| Baclofen | Baclofen | 43 | 28 |
| Topiramate | Topiramate | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 22 |
| Nexletol | Bempedoic Acid | 40 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 38 | 16 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Jardiance | Empagliflozin | 33 | 12 |
| Furosemide | Furosemide | 32 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Testosterone | Testosterone | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 11 |
| Metformin Hcl | Metformin Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Metronidazole | Metronidazole | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Ubrelvy | Ubrogepant | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Prolia | Denosumab | 19 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Taltz Autoinjector | Ixekizumab | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $35,236.34 · 83 records | Corcept Therapeutics | Korlym, Ozempic, QULIPTA, Rybelsus, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Korlym play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error